



DISBURSED TO 21 MAR 2003

**PATENT APPLICATION**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Glaucia PARANHOS-BACCALA et al.

Group Art Unit: 1634

Application No.: 09/869,927

Examiner: A. Chakrabarti

Filed: August 17, 2001

Docket No.: 110048

For: ENDOGENOUS NUCLEIC ACID FRAGMENT ASSOCIATED WITH AN  
AUTOIMMUNE DISEASE, LABELING METHOD AND REAGENT

**REQUEST FOR CORRECTION OF PALM RECORDS**

Director of the U.S. Patent and Trademark Office  
Washington, D.C. 20231

Sir:

Attached is a photocopy of the original filing receipt on which errors have been corrected in red. These errors are being brought to the attention of the Patent and Trademark Office so that it may correct its records.

Respectfully submitted,

*Melanie L. Mealy*  
William P. Berridge  
Registration No. 30,024

Melanie L. Mealy  
Registration No. 40,085

RECEIVED

APR 23 2003

TECH CENTER 1900/2900

Date: March 21, 2003

OLIFF & BERRIDGE, PLC  
P.O. Box 19928  
Alexandria, Virginia 22320  
Telephone: (703) 836-6400

DEPOSIT ACCOUNT USE  
AUTHORIZATION  
Please grant any extension  
necessary for entry;  
Charge any fee due to our  
Deposit Account No. 15-0461




## UNITED STATES PATENT AND TRADEMARK OFFICE

MLM

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/869,927	08/17/2001	1645	1564	110048	5	18	5

Oliff & Berridge  
PO Box 19928  
Alexandria, VA 22320



CONFIRMATION NO. 1582

FILING RECEIPT



\*OC000000007277975\*

Date Mailed: 01/10/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Glaucia Paranhos-Baccala, Lyon, FRANCE;  
Francois Mallet, Villeurbanne, FRANCE;  
Cecile Voisset, London WC1H 9QW, UNITED KINGDOM;

**Domestic Priority data as claimed by applicant**

THIS APPLICATION IS A 371 OF PCT/FR00/00144 01/21/2000

**Foreign Applications**

FRANCE 99/00888 01/21/1999

RECEIVED  
APR 28 2003  
TECH CENTER 1609/2000

**Projected Publication Date:** Not Applicable, filed prior to November 29, 2000

**Non-Publication Request:** No

**Early Publication Request:** No

**Title**

Endogenous  
Endogenous nucleic fragment associated with an autoimmune disease,  
reagent

labeling  
marking method and

**Preliminary Class**

435

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).